Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 9/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 8/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30796734 | 0.94 | CRBN (0.45) | TMEM97SIGMAR1CRBNIKZF3CXCR3 | |
| SCHEMBL27446193 | 0.86 | CRBN (0.43) | TMEM97SIGMAR1CRBNIKZF3CXCR3 | |
| SCHEMBL26954254 | 0.83 | CRBN (0.52) | CRBNIKZF3DDB1 | |
| SCHEMBL20812031 | 0.81 | SMN1; SMN2 (0.54) | CRBNIKZF3SMN1; SMN2NPC1RAB9A | |
| SCHEMBL27453731 | 0.81 | CRBN (0.44) | CRBNIKZF3DDB1GAA | |
| SCHEMBL20812027 | 0.81 | CRBN (0.51) | CRBNIKZF3SMN1; SMN2NPC1RAB9A | |
| SCHEMBL27453719 | 0.81 | CRBN (0.44) | CRBNIKZF3DDB1GAA | |
| SCHEMBL30659395 | 0.80 | CRBN (0.45) | CRBNIKZF3DDB1 | |
| SCHEMBL31443743 | 0.79 | CRBN (0.70) | CRBNIKZF3DDB1 | |
| SCHEMBL27453710 | 0.79 | CRBN (0.41) | CRBNIKZF3DDB1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539849-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2023244764-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | SMARCA2, SMARCE1, SMARCA1 | TMEM97 1787/4885SIGMAR1 2407/4885CRBN 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.